HoxC11 CRISPR/Cas9 KO Plasmid (h): sc-406796
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- HoxC11 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the HoxC11 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: HoxC11 Antibody (HOX5J232): sc-81293
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
HoxC11 CRISPR/Cas9 KO Plasmid (h) | sc-406796 | 20 µg | $397.00 |
Overview
HOXC11 encodes the homeobox transcription factor HoxC11, a DNA-binding regulator that contributes to anterior–posterior patterning and regional identity during development through sequence-specific control of gene expression programs. In differentiated tissues, HoxC11 can influence cellular differentiation states and lineage-associated transcriptional networks, interacting with cofactors and chromatin regulatory machinery to shape context-dependent transcription. Dysregulated HOXC11 expression has been reported in multiple tumor contexts and is frequently studied as part of broader HOX gene network alterations that impact proliferation, invasion, and cellular plasticity. As a transcriptional regulator, HoxC11 is relevant to investigations of developmental gene regulatory circuits, epigenetic control of cell identity, and oncogenic reprogramming.
HoxC11 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the HOXC11 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the HOXC11 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the HOXC11 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish HoxC11 protein expression.
This CRISPR knockout system enables efficient generation of HOXC11-deficient cell models for investigation of HoxC11 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting HOXC11 exon(s) critical for HoxC11 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple HOXC11 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by HoxC11 CRISPR/Cas9 KO Plasmid (h) and HoxC11 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the HOXC11 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by HoxC11 HDR Plasmid (h) and HoxC11 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by HOXC11 homology arms to support homology-directed repair at defined HOXC11 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.